Featured
-
-
Article
| Open AccessDurvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.
- Patrick M. Forde
- , Valsamo Anagnostou
- & Suresh S. Ramalingam
-
Letter |
Deep learning-based classification of mesothelioma improves prediction of patient outcome
Deep convolutional neural networks predict survival of mesothelioma patients and identify histological features associated with outcome that transcend current histological classifications.
- Pierre Courtiol
- , Charles Maussion
- & Thomas Clozel
-
Letter |
Loss of BAP1 function leads to EZH2-dependent transformation
BAP1 regulation of EZH2 provides therapeutic opportunities in cancer.
- Lindsay M LaFave
- , Wendy Béguelin
- & Ross L Levine